KTTA - Pasithea conducts 1-for-20 reverse stock split gets FDA okay for study
2024-01-02 09:11:26 ET
More on Pasithea Therapeutics
- Pasithea stock soars as high as 190% on preclinical data
- Pasithea stock jumps 12% on update for anti-tumor drug PAS-004
- Financial information for Pasithea Therapeutics
For further details see:
Pasithea conducts 1-for-20 reverse stock split, gets FDA okay for study